Bladder Cancer Clinical Trials & Research

Clinical trials offer bladder cancer patients the opportunity to be among the first to benefit from breakthrough treatment options, before they become widely available. Sometimes, it is mistakenly believed that participating in a clinical trial means that the patient will become a "guinea pig," either testing a drug or procedure that has never before been used or unknowingly receiving a placebo, but this could not be further from the truth. In reality, cancer treatments that are in the clinical trial phase have already undergone extensive testing for safety, and in the rare instances that placebos are used in clinical trials, participants are made fully aware of this possibility and are never denied access to other treatments they may need. Furthermore, clinical trial participants can choose to withdraw from the program at any time.

Are You a Candidate for a Bladder Cancer Clinical Trial?

The purpose of clinical trials, for bladder cancer or any other type of cancer, is to compare innovative new therapies with standard treatments (standard treatments that are considered the most advanced options currently available). Any patient can be considered for participation in a clinical trial, but they must meet the inclusion criteria for the particular study. These criteria may include factors such as:

  • The type of cancer
  • The patient’s gender
  • The patient’s age
  • Past treatments
  • The staging, or extent, of the cancer

For the most groundbreaking treatments and clinical trials, bladder cancer patients should look to high-volume cancer facilities, like Moffitt Cancer Center, that have a specialty program concentrated on urologic cancers. Moffitt boasts a robust clinical trials program and is home to a vast research team that’s comprised of a wide range of professionals, including physician-scientists, research data specialists and oncologists who specialize solely in the treatment of bladder cancer. For our extensive research efforts, Moffitt has been designated a National Cancer Institute Comprehensive Care Center – the only one based in Florida.

If you’d like to learn about specific bladder cancer clinical trials available at Moffitt, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.


calledFromCancerPage=True - substr=bladder

Open Clinical Trials:

Showing of 50


A Phase II Open Label Single Arm Study of Adjuvant Nivolumab following Chemo-Radiation in localized Muscle-Invasive Bladder Cancer (NEXT)

Disease Site: Urinary Bladder

View Trial Details


A Randomized Phase II Study of Atezolizumab (MPDL3280A) plus Recombinant Human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma

Disease Site: Urinary Bladder, Urothelial Cancer

View Trial Details


A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

Disease Site: Urothelial Cancer, Urinary Bladder

View Trial Details


QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Disease Site: Urinary Bladder

View Trial Details


S1806, Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Disease Site: Urinary Bladder

View Trial Details


A Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

Disease Site: Urinary Bladder

View Trial Details


An Exploratory, Open-label, Multicenter Phase 1b Trial to Evaluate Safety and Efficacy of Sym021 (Anti-PD-1) in Combination with Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3) or Sym023 and Irinotecan in Patients with Recurrent Advanced Biliary Tract Carcinomas

Disease Site: Liver, Lung, Other Female Genital, Urinary Bladder

View Trial Details


A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)

Disease Site: Any Site, Breast, Colorectal, Endometrial/Uterine, Extrapulmonary small cell lung cancer, Gallbladder, Gastric / Stomach, Gastrinoma, Gastrointestinal, Liver, Lung, Non small cell lung cancer, Other genitourinary, Other GI, Pancreas, Prostate, Reproductive System, Urinary Bladder, Uterus

View Trial Details


Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Disease Site: Other Urinary, Urinary Bladder, Urothelial Cancer

View Trial Details


A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Disease Site: Brain and Nervous System, Breast, Ill-Defined Sites, Lung, Other Digestive Organ, Urinary Bladder, Brain metastasis, Leptomeningeal (LMD)

View Trial Details


A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors (DRAGON)

Disease Site: Any Site, Lung, Melanoma, skin, Urinary Bladder

View Trial Details


A First-in-Human, Two-Part, Open-Label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 as Monotherapy and in Combination with an Immune Checkpoint Inhibitor, in Patients with Advanced-Stage, Relapsed/Refractory Cancer (EVICTION Study)

Disease Site: Any Site, Breast, Colon, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Ovary, Prostate, Stomach, Urinary Bladder

View Trial Details


Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Disease Site: Breast, Lung, Melanoma, skin, Ovary, Pancreas, Urinary Bladder

View Trial Details